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Missing outcome data constitute a serious threat to the validity and precision of
inferences from randomized controlled trials. In this paper, we propose the use of
a multistate Markov model for the analysis of incomplete individual patient data
for a dichotomous outcome reported over a period of time. The model accounts
for patients dropping out of the study and also for patients relapsing. The time of
each observation is accounted for, and the model allows the estimation of time‐
dependent relative treatment effects. We apply our methods to data from a study
comparing the effectiveness of 2 pharmacological treatments for schizophrenia.
The model jointly estimates the relative efficacy and the dropout rate and also allows
for a wide range of clinically interesting inferences to be made. Assumptions about
the missingness mechanism and the unobserved outcomes of patients dropping out
can be incorporated into the analysis. The presented method constitutes a viable
candidate for analyzing longitudinal, incomplete binary data.
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1 | INTRODUCTION
Missing outcome data are frequently encountered in random-
ized control trials and may compromise the validity of
inferences and increase the uncertainty in the effects of an
intervention.[1] Missing data constitute a major problem for
certain areas of medicine. Studies in mental health usually
have a high dropout rate due to the nature of the conditions
and the treatments involved. Studies in schizophrenia tend
to have a dropout rates as large as 50% or even higher, which
leads to large amounts of missing outcome data.[2]
In the presence of missing data, the researcher can follow a
number of different approaches for the analysis. The simplest
of all is to analyze only patients that completed the study after
excluding patients that dropped out (complete case analysis,
CCA). This approach, however, will lead to a loss of precision
and to biased results when data are not missing completely at
random (MCAR).[1,3–6] An MCAR mechanism is implausible
in many clinical contexts, where dropout rates are informa-
tive: In psychiatric trials, for example, dropout is strongly
correlated to the clinical outcome and is often considered a
proxy to both treatment efficacy and acceptability. A common
way to overcome the missing data problem is to employ some
form of imputation, for example, the last observation is
carried forward (LOCF),[6] multiple imputations,[6,7] or to
use regression methods that do not impute data such as the
mixed model for repeated measures (MMRM)[8,9] and
selection models.[10] The various available methods make
different assumptions about the unobserved outcomes. The
missingness mechanism, however, is essentially untestable.
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Thus, researchers sometimes choose to analyze dropout
separately as an additional (and often primary) outcome.
The aim of this paper is to present an alternative method
for analyzing incomplete dichotomous outcomes. We do this
by employing a Markov model previously proposed, after
adapting it for the missing outcome data context. Markov
models offer an intuitive approach for modeling patients'
transitions between a number of discrete states over
time[11–14] and have been used in a variety of clinical settings
such as modeling terminal and nonterminal events in coronary
heart disease,[15] cancer screening,[16] and HIV progres-
sion.[17] Markov models can be either discrete time (where
transitions can only occur at fixed time points) or continuous
time (where transitions can occur at any time).[18] Continu-
ous‐time Markov models have both theoretical and practical
advantages over their discrete‐time counterparts.[18] The
model we use in this paper is a continuous‐time Markov
model with 3 states,[19] and our method is focused on the
reconstruction of the various paths a patient may follow across
these states. It can be used to model dichotomous, patient‐
level outcomes reported over different time points while
accounting for patients dropping out and for patients relaps-
ing. To the best of our knowledge, Markov models have not
been previously used to analyze missing patient outcomes.
The analysis is focused on the estimation of the transition rates
between the different states rather than probabilities of transi-
tions which depend on the elapsed time. Using these rates, the
model can provide an array of clinically interesting estimates
regarding treatments' effects on efficacy, acceptability, and
relapse at any time point. We also expand the model by
including additional unobserved states so as to accommodate
assumptions regarding the missingness mechanism and the
outcomes of patients dropping out. We adopt a Bayesian
framework throughout this paper because it offers increased
flexibility in modeling. We fit all presented models employing
Markov chain Monte Carlo (MCMC) techniques in
WinBUGS. A frequentist approach is also possible by using
for example the msm package in R.[20]
The paper is structured as follows: in section 2, we pro-
vide a brief description of the data that motivate our methods.
In section 3, we present the model, we discuss how to
estimate the model's parameters from the available data, we
describe how the model can be used to make various infer-
ences on the relative treatment effects, and we present model
extensions. In section 4, we present the results from the
application, and in section 5, we discuss the advantages and
the limitations of our approach. In Appendix S1, we provide
mathematical details, additional results as well as the
WinBUGS code that we use to implement the model.
2 | DATA DESCRIPTION
To exemplify our methods, we use data from a randomized
controlled trial comparing amisulpride with risperidone for
patients in the acute phase of schizophrenia.[21] For each
patient and for each time point, the study provides information
on whether or not the patient is a responder (with response
defined as a 50% reduction in the Brief Psychiatric Rating
Scale from baseline) or has dropped out of the study. A total
of 115 patients were randomized in the amisulpride arm and
113 in the risperidone arm. Patients were followed‐up at 1,
2, 4, 6, and 8 weeks after starting to receive medication. The
dropout rates were large for both study arms (31% for
amisulpride and 26% for risperidone). Once a patient
dropped out of the study, the trialists could not collect
any efficacy data. No information was available for the
reasons of dropping out. For the purposes of this paper,
we coded as dropouts all patients that missed a visit and
all subsequent ones. In the dataset, we were given access
there were no intermediate missing values; that is, there
were no missing observations for patients still in the study.
In section 1 of Appendix S1, we provide the aggregated
outcome data at each time point.
3 | METHODS
In this section, we present the model and we discuss how to
estimate the model parameters from the available data and
how to use these estimates to make inferences about the
relative treatment effects.
3.1 | The 3‐state model
The basic model that we use comprises 3 different Markov
states and is sometimes termed the “illness‐death” model.[14]
State 1 is the starting state for all patients (which we call
“[observed] nonresponse”), state 2 corresponds to a 50%
reduction of the score in the Brief Psychiatric Rating Scale
from baseline (“[observed] response”), and state 3 corre-
sponds to the patient dropping out of the study (“study
discontinuation”). Transitions between states 1 and 2 are
allowed in both directions. State 3 is an all‐absorbing state;
that is, no backward transitions are allowed and patients
dropping out of the study cannot re‐enter. Note, however, that
a patient may miss a visit without dropping out of the study;
in such cases, the corresponding observation is missing but
the patient is not coded in the dropout state. The 3 states of
the model and the allowed transitions are depicted in
Figure 1A. The 4 γ presented in the figure are the target
parameters of the model, which we aim to estimate from
the available data.
We employ the Markov assumption[14] that the probabil-
ity of a transition from a state to another does not depend
on the previous states visited or on the time spent in current
state, and we also assume that the transition rates γΧΨ are
constant through time and are common for all patients
randomized in the same treatment arm. The model can be
extended to include patient‐level random effects in the
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transition rates to make the transition rates dependable on
patient‐level covariates (as we discuss in section 3.5) or
to account for time‐dependency in the transition rates
(see section 5).
For patient k, randomized in treatment arm Tk, (Tk=1 , 2),
the matrix of transition rates is defined as follows:
GTk ¼
− γTk12 þ γTk13
! "
γTk12 γ
Tk
13
γTk21 − γ
Tk
21 þ γTk23
! "
γTk23
0 0 0
0B@
1CA
Each diagonal element in row q (where q=1 , 2 , 3) in the
matrix shows the total rate of transition out‐of‐state q. Off‐
FIGURE 1 (A) A 3‐state model with transitions between states 1 and 2 allowed both ways. State 3 is an absorbing state and corresponds to a patient dropping
out of the study. Each transition from state Χ to state Ψ is associated with a transition rate γΧΨ. (B‐F) Four‐state models with 2 unobserved states incorporating
different assumptions about the missingness mechanism
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diagonal elements show how transitions from state q are dis-
tributed to all other states. For example,GTk11 ¼ − γTk12 þ γTk13
! "
,
which means that patients leave state 1 at a rate of γTk12 þ γTk13
and these patients either go to state 2 (with a transition rate
equal to GTk12 ¼ γTk12 ) or to state 3 (with a transition rate
equal to GTk13 ¼ γTk13). Because the state‐space is exhaustive,
the total number of patients in the system remains constant,
and each row of the GTk matrix sums to 0. State 3 is an
all‐absorbing state, so the elements of the third row are
all 0.
The matrix of transitions, GTk, is related to the matrix of
the transition probabilities ΠTk Δtð Þ,
ΠTkðΔtÞ ¼
πTk1;1 Δtð Þ πTk1;2 Δtð Þ πTk1;3 Δtð Þ
πTk2;1 Δtð Þ πTk2;2 Δtð Þ πTk2;3 Δtð Þ
0 0 1
0BB@
1CCA:
The ΧΨ element of this matrix gives the probability of a
patient receiving treatment Tk, starting at state Χ to be found
at state Ψ after time Δt. So, a patient situated at state 2 after
time Δt will be at states 1, 2, or 3, with probabilities
πTk2;1 Δtð Þ, πTk2;2 Δtð Þ, and πTk2;3 Δtð Þ, respectively; of course, these
probabilities must add up to 1. A patient situated at state 3
will remain there, so that πTk3;1 Δtð Þ and πTk3;2 Δtð Þ are 0, while
πTk3;3 Δtð Þ equals 1 for all time points.
The transition probability matrix ΠTk Δtð Þ can be calcu-
lated by using the transition rate matrixGTk via Kolmogorov
forward equation dΠ
Tk Δtð Þ
d Δtð Þ ¼ ΠTk Δtð ÞGTk . This is a differ-
ential equation giving the evolution of ΠTk over time. Under
regularity conditions which are readily satisfied in practice
(and which regard the derivatives of the probability
functions[22]), the solution is given by ΠTk Δtð Þ ¼
eΔtGTk ¼ ∑∞n¼0
Δtn
n!
GTk
# $n
. Because GTk is a matrix, a
closed‐form solution cannot be always obtained. For the spe-
cial case of a 3‐state model presented in Figure 1A, analytic
closed‐form solutions are available.[19] We first define the
hTk quantities as:
hTk ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
λ1Tk−λ2Tk
# $2 þ 4γTk12 γTk21 ; λTkX ¼ ∑ψ≠xγTKXψr
(1)
where λΧTk is the transition rate from state Χ to all other states.
The transition probabilities are given by the following
equations (after dropping the Tk index denoting treatment
arm for simplicity):
π1;1 Δtð Þ ¼ −λ1 þ λ2 þ hð Þe
−12 λ1þλ2−hð ÞΔt þ λ1−λ2 þ hð Þe−12 λ1þλ2þhð ÞΔt
2h
(2)
π1;2 Δtð Þ ¼
−λ1 þ λ2 þ hð Þ λ1−λ2 þ hð Þ e−12 λ1þλ2−hð ÞΔt−e−12 λ1þλ2þhð ÞΔt
# $
4hγ21
(3)
π1;3 Δtð Þ ¼ 1−π1;1 Δtð Þ−π1;2 Δtð Þ (4)
π2;1 Δtð Þ ¼
γ21 e−
1
2 λ1þλ2−hð ÞΔt−e−12 λ1þλ2þhð ÞΔt
# $
h
(5)
π2;2 Δtð Þ ¼ λ1−λ2 þ hð Þe
−12 λ1þλ2−hð ÞΔt þ −λ1 þ λ2 þ hð Þe−12 λ1þλ2þhð ÞΔt
2h
(6)
π2;3 Δtð Þ ¼ 1−π2;1 Δtð Þ−π2;2 Δtð Þ (7)
Given the 4 transition rates, all transition probabilities
included in the ΠTk matrix can be computed as a function
of time. In what follows, we will see how to use the available
data to estimate the 4 parameters of the model (the 4
TABLE 1 Data for Patient k
Time point t0 = 0 t1 t2 tF
State Skm at time tm
1 2 1 3
Observed
nonresponse
Observed
response
Observed
nonresponse
Study
discontinuation
Data coded as vectors xk0 ¼ 1; 0; 0ð Þ xk1 ¼ 0; 1; 0ð Þ xk2 ¼ 1; 0; 0ð Þ xkF ¼ 0; 0; 1ð Þ
Observed transition – 1→ 2 2→ 1 SkF−1→3
Transition probabilities being informed by the observed transition – πTk1;1 Δtð Þ πTk2;1 Δtð Þ πTkSkF−1 ;1 Δtð Þ
πTk1;2 Δtð Þ πTk2;2 Δtð Þ πTkSkF−1 ;2 Δtð Þ
πTk1;3 Δtð Þ πTk2;3 Δtð Þ πTkSkF−1 ;3 Δtð Þ
The numbers show an example where a patient responds to treatment at time point t1, relapses to nonresponse at time point t2, and has left the study at time point tF. Each
transition informs the corresponding set of probabilities and consequently the transition rates.
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transition rates) and how to make inferences on relative treat-
ment effects. Before this, we introduce some notation that
considerably simplifies the analysis.
3.2 | Data notation
Let us denote t1, t2 … tF as the time points at which the
observations for each patient are collected. To each patient
k, randomized in treatment arm Tk, and for each time point
tm (m=1 , 2 , …F), corresponds an observation of his state,
Skm (1, 2, or 3). We also code the patient's state by using a
vector xkm. This vector conveys the same information as S
k
m
and takes values (1, 0, 0) for state 1 (observed nonresponse),
(0, 1, 0) for state 2 (observed response), and (0, 0, 1) for state
3 (study discontinuation). All patients start from the nonre-
sponse state, so that xk0 ¼ 1; 0; 0ð Þ∀i; k: These definitions
are summarized in Table 1. In section 2 of Appendix S1,
we provide a list of all notations used in this paper.
3.3 | Estimating the model parameters
Our target is to estimate the transition rates from the transi-
tion probabilities that are directly estimable from the data.
A transition from a starting state Skm (where the patient was
observed to be at time tm) is controlled by the transition
probabilities πTk
Skm;1
Δtð Þ; πTk
Skm;2
Δtð Þ , and πTk
Skm;3
Δtð Þ given in
Equations 2 to 7, where Δt= tm+ 1− tm corresponds to the
time interval between the 2 observations. In the example pre-
sented in Table 1, a patient was situated at state 1 at time t0
(so that Sk0 ¼ 1) and he was observed to be at state 2 in the
next observation at time t1 (Sk1 ¼ 2). This corresponds to
a transition 1→ 2 in time Δt= t1− t0. This transition
provides information about the corresponding transition
probabilities πTk
Sk0;1
Δtð Þ ¼ πTk1;1 Δtð Þ , πTkSk0;2 Δtð Þ ¼ π
Tk
1;2 Δtð Þ , and
πTk
Sk0;3
Δtð Þ ¼ πTk1;3 Δtð Þ and informs the estimation of the 4
transition rates. Likewise, the second transition is a relapse
(transition 2→1); the corresponding time is Δt= t2− t1,
and it informs the probabilities πTkSk1;1
Δtð Þ ¼ πTk2;1 Δtð Þ ,
πTkSk1;2
Δtð Þ ¼ πTk2;2 Δtð Þ, and πTkSk1;3 Δtð Þ ¼ π
Tk
2;3 Δtð Þ, which in turn
give information about the 4 transition rates γ. Note here that a
patient remaining at the same state for 2 consecutive observa-
tions also informs the corresponding probabilities. Also note
that if a patient misses a visit without dropping out of the
study (i.e., data on at least 1 subsequent visit is available),
the likelihood is informed by the remaining observations
and their corresponding Δt. No further assumption is needed
to employ the model in such a case.
In summary, each observed transition provides informa-
tion about 3 of 6 transition probabilities included in
ΠTk Δtð Þ. These 3 probabilities are selected for each transi-
tion Skm→S
k
mþ1 according to the starting state (S
k
m ) and can
be written as the vector ( πTk
Skm;1
Δtð Þ; πTk
Skm;2
Δtð Þ; πTk
Skm;3
Δtð ÞÞ ¼
xkm∙ΠTk Δtð Þ . The likelihood for the observation on patient
k, treatment Tk, at the (m+1) time point is given by a multi-
nomial distribution:
xkmþ1∼Multinomial x
k
m∙Π
Tk Δtð Þ; 1! " (8)
The full likelihood of the data can be obtained as
L ¼ ∏
Np
k¼1
∏
F−1
m¼0
fM x
k
mþ1; x
k
m∙Π
Tk Δtk;mþ1
! "
; 1
! "
where Np denotes the total number of patients, fM is the prob-
ability mass function of the multinomial distribution, and
Δtk ,m + 1 is the time interval between observations m and m
+1 for patient k. In this paper, we adopt a Bayesian frame-
work by using MCMC software to estimate the parameters
of the model. One can also use frequentist methods to maxi-
mize this likelihood; see for example Refs [[13,23]].
3.4 | Making inferences on relative treatment effects
Having estimated the transition rates for each treatment arm,
we can reuse Equations 2 to 7 to estimate the probabilities of
transition from a state to another, for any period of elapsed
time. Note that the probability of making a transition between
2 states does not depend on time t per se; rather, it depends on
the elapsed time interval Δt considered. So, for a patient in a
given state at time t, the probability of the patient being found
in any state at time t+Δt will only depend on the elapsed time
Δt and not on t.
Subsequently, inference on relative treatment effects can
be made at any time point deemed to be clinically interesting
as δ ¼ l π1Χ;Ψ Δtð Þ
# $
−l π2Χ;Ψ Δtð Þ
# $
, where l is a link function.
For instance, if l(x) = logit(x), X=1, and Ψ=2, then δ corre-
sponds to the log odds ratio for efficacy among completers. If
l(x)= ln (x), X=2, and Ψ=3, then we obtain the log relative
risk for dropping out after responding. In section 3 of the
Appendix, we discuss in detail the relative effect measures
that can be obtained by using the probabilities of transitions.
If multiple studies are analyzed so as to be included in a
meta‐analysis, then it would be appropriate to pool on the
log‐rate‐ratio scale. Predictions on probabilities can then be
made at any chosen time point.
One advantage of the proposed Markov model is that it
can also provide estimates which might be of interest to clini-
cians and which cannot be obtained by the currently available
approaches for analyzing longitudinal data. These include the
following:
a. The probability for a patient to drop out due to
inefficacy. This is defined as the probability to dropout
after time Δt without ever experiencing a response to
the treatment, that is, to drop out directly from the
(observed) nonresponse state.
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b. The probability of a patient to drop out after responding.
This is defined as the probability to dropout straight after
the (observed) response state.
c. The expected time spent (ETS) in each state can be a use-
ful estimate as it summarizes the effect of the treatment
in an easy‐to‐understand manner.
The formulas for these quantities are presented in section
4 of the Appendix.
Note that we have assumed all 4 transition rates to be
treatment‐specific. Depending on the clinical context, it
might be desirable to set some of them equal across treatment
arms.[24] For example, a common γ23 can be assumed for both
treatments when the rate at which responders drop out is
believed to be independent of the treatment received.
3.5 | Including random effects and patient‐level
covariates
Until now, we have assumed transition rates to be common
for all patients within each treatment arm. The model can
be extended to include random effects after assuming that
the transition rates for patients randomized in a treatment
arm are not fixed but exchangeable, that is, coming from a
common distribution.
More specifically, the logarithm of the transition rate for
γkΧΨ for patient k can be assumed to follow a normal distribu-
tion, ln γkΧΨ
! "
∼N ln γTkΧΨ
! "
; τTkΧΨ
! "2# $
, where τTkΧΨ is the stan-
dard deviation of the random effects for the ΧΨ transition
rate for treatment Tk. Various modeling assumptions can
be made about the random effects structure; for example,
one can include random effects in some or all of the transi-
tions rates, and the model can be further simplified by
allowing a common τ2 for all transition rates across all
treatments.
Covariates can also be easily included in the model by
setting ln
!
γkΧΨÞ∼N ln γTkΧΨ
! "þ bTkΧΨCk; τTkΧΨ! "2# $ , where Ck
is a patient‐level covariate for patient k. In this equation,
γΧΨTk corresponds to the average, treatment‐specific transi-
tion rate centered at 0 value of the covariate Ck. One can
follow different approaches to model the coefficient b, such
as to assume a common value for some of them (e.g., it might
be reasonable to set bTk13 ¼ bTk23) or to assume common coeffi-
cients across treatments (to allow for a bΧΨ instead of bΧΨTk );
choices should be dictated by the clinical context at hand and
after taking into account expert clinical opinion.
With these changes, all probabilities of transitions pre-
sented in the analyses of the previous sections now also
depend on patient covariates (i.e., we need to write πk1;2
instead of πTk1;2 ), but the rest of the analysis remains
unchanged. Adding more covariates is also straightforward.
Note that the model without patient‐level random effects
and covariates is a population‐averaged approach; that is, it
does not distinguish observations belonging to the same or
different individuals. By including random effects and/or
covariates in the model, we allow for patient‐specific terms
in the analysis.
The general 3‐state model assumes that the 2 dropout
rates γ13 and γ23 may be different, and thus the transition
into the dropout state depends on the current state of the
patient. This corresponds to a missing at random (MAR)
assumption; that is, dropout is dependent on observed data
(state of the patient). Missing at random is also assumed
when including covariates for γ13 and γ23 in the analysis.
In that case, dropout depends also on (observed) patient
characteristics. For an MCAR assumption, one would need
to set γ13= γ23 and to exclude any covariates from the anal-
ysis. In that case, the dropout rate does not depend on
whether or not a patient has responded to the treatment or
any other observable or unobservable characteristics. In the
following section, we discuss how to expand the model to
also accommodate an MNAR assumption and how to use
the presented framework to make predictions on unobserved
outcomes.
3.6 | Modeling unobserved response
The analysis presented so far essentially treats response and
dropout state as 2 mutually exclusive outcomes. However, it
is often of interest to researchers to make inferences about
treatment effects in patients that drop out. Moreover, it has
been recommended to perform sensitivity analyses regarding
the unobserved data to assess the robustness of findings
under different scenarios regarding the missingness
mechanism.[9,25]
One can extend the method we have presented so far by
assuming that patients who drop out continue to undergo
transitions between an unobserved nonresponse and an
unobserved response state. Several adaptations of such a
4‐state model are depicted in Figure 1B to F. The quantity
of interest is now the probability of either observed or unob-
served response, that is, πTk1;2 þ πTk1;5.
In section 6 of the Appendix, we provide the analytic
formulas needed to calculate the transition probabilities for
the general 4‐state model, given the 8 transition rates
(γ12 , γ21 , γ14 , γ15 , γ24 , γ25 , γ45 , γ54). These transition rates,
however, cannot be directly estimated from the observed
data; unobserved data (the outcomes of dropout patients)
would also be needed for fitting this model. Thus, to use
the 4‐state model, one needs to first fit the 3‐state model of
Figure 1A and estimate the corresponding transition rates.
At the second stage, one can use the 4‐state model (after
making assumptions regarding the missingness mechanism)
to make predictions about the outcome in the patients who
have dropped out. Several scenarios are discussed below:
1. Missing completely at random can be modeled by setting
γ14= γ25, γ24= γ15=0, and also γ45= γ12 and γ54= γ21
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(Figure 1B). The first 2 of these equations impose the
assumption that the dropout rates do not depend on either
observed or unobserved data, and that they are equal
among responders and nonresponders. The latter 2 of
these equations imply that the transitions between the
unobserved response and nonresponse states follow the
same pattern as the transitions of patients still in the
study. Essentially, these 5 equations imply that dropout
and response are 2 independent procedures. Note that
for an MCAR assumption, the transition rates γ14 and
γ25 need to be independent of any covariates.
2. Setting γ14= γ15≠γ24= γ25 corresponds to dropout rates
being different across responders and nonresponders
but to only depend on observed data (MAR). This is
depicted in Figure 1C. Again, one should also assume
that γ45= γ12 and γ54= γ21, implying that unseen transi-
tions can be predicted based on the observed data.
3. In amissing not at random (MNAR) scenario (Figure 1D),
the dropout rates depend on both observed and
unobserved outcomes, and the unobserved outcomes
cannot be predicted solely by using the observed data.
This can be modeled by setting γ14≠ γ15 and γ24≠ γ25.
With this formulation, the dropout rate depends on both
observed data (state before dropping out) as well as the
unobserved data (state after dropping out). The transition
rates between the unobserved states can then be assumed
to be equal to the corresponding observed ones, that is,
γ45= γ12 and γ54= γ21, or researchers might adopt differ-
ent scenarios to better reflect beliefs about the response
patterns of dropout patients.
4. The “LOCF‐like” missingness scenario: All dropouts
remain in the last observed state. This can be
accomplished in the 4‐state scenario by setting
γ15= γ24= γ45= γ54=0. Unlike the usual LOCF
approach, however, estimation of transition rates and
probabilities uses all available observations and not just
the last observation from each patient. This is depicted in
Figure 1E. Note that for LOCF, MCAR is necessary, but
not sufficient assumption.[9]
5. The “All dropout failure” scenario: this can be achieved
by setting γ14= γ24=0 and is depicted in Figure 1F. This
scenario may be of interest to apply in only one of the
treatment arms. For example, patients receiving placebo
may be expected to drop out only due to lack of effective-
ness (but not due to adverse events).
Note that the 4‐state model can account for uncertainty
regarding the missing values by using a stochastic approach
to model the patient trajectories after dropping out (this holds
for scenarios 1, 2, and 3 above but not for scenarios 4 and 5
which do not model uncertainty in the dropout patients).
Regarding how to choose between these models, we think
that the choice should be primarily dictated by the research
question, the medical context, and the plausibility of the
assumptions that it involves. Different models use different
assumptions regarding the dropout mechanism. In a situation
where, for example, dropout is thought to be irrelevant to the
outcome, model 1 will be sufficient. If, on the other hand,
dropout is mainly due to inefficacy, an MNAR assumption,
such as in model 3, will be more realistic. Measures of model
fit and simulation studies might also help in deciding among
models employing similar assumptions.
One of the most popular approaches for analyzing
repeated observations of a dichotomous outcome is to
employ some form of MMRM. For the case of a binary out-
come, a logistic link function is commonly used. An example
of an MMRM with random time trends is the following:
logit πk;j
! " ¼ β0 þ β1tj þ β2Tk þ uktj þ εkj (9)
In this model, πk , j denotes the probability of response for
patient k, at time tj; it corresponds to π1 , 2 + π1 , 5 for the
4‐state model. Tk denotes the treatment received (assumed
here to be a binary covariate); uk is a random, subject‐specific
slope; and εkj is the residual. Residuals are assumed to be cor-
related for each patient across time points, that is, εk~N(0,Σ),
with Σ being a variance‐covariance matrix that can be esti-
mated from the data. This model can be expanded by adding
higher order terms of tj, treatment‐time interaction terms,
patient‐level covariates, or by assuming a structure on Σ.
Other link functions could be used instead of logit as long
as they map (0, 1) to (−∞,∞).
Instead of using an arbitrarily chosen link function to
model the time dependency of the probability of response,
in this paper, we have used a method that models the under-
lying mechanism of disease progression, starting from
elementary concepts such as the transition rates. The corre-
sponding expressions, for example, Equation 2, are somewhat
similar to Equation 9, in the sense that they are both exponen-
tial functions of t.
4 | ANALYSIS OF THE SCHIZOPHRENIA
DATA
In this section, we apply our methods for the study described
in section 2. We consider the Markov assumption to be a use-
ful approximation for this example; that is, we assume that
the patients' disease progression and dropout rates are only
affected by their current state.
4.1 | Model implementation
We fit our model by WinBUGS; the code can be found in
section 7 of the Appendix. We assume minimally informative
prior distributions for the logarithm of the γs in each arm,
ln γΧΨiÞ∼dunif −10; 5ð Þ
!
. These limits are chosen arbitrarily,
for estimation reasons.[24] Because these refer to a logarith-
mic scale, including bigger or smaller values corresponds to
extremely big and small transition rates which may hinder
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convergence; in practice, changing these limits has little
impact on the results. We assume random effects on the
log‐transition rates as described in section 3.5, assuming a
common heterogeneity τ~ dunif(0, 1). A burn‐in period of
20 000 iterations was used for the MCMC simulation. All sta-
tistics that we present in the next section were obtained from
the posterior distributions of the parameters, based on 2 inde-
pendent chains with 20 000 iterations each. Convergence was
confirmed by using the Brooks‐Gelman‐Rubin criterion.[26]
4.2 | Results
We first fit the 3‐state model depicted in Figure 1A, assuming
γ13≠ γ23. We present the estimates of the 4 transition rates for
each treatment in Table 2, and we also give the relative treat-
ment effects of the log transition rate ratios. The heterogene-
ity standard deviation for the log‐transition rates (assumed
common) was estimated to be 0.64 (95% credible interval
[CrI] 0.31 to 0.92).
An interesting observation is that all rates are higher in
the amisulpride than in the risperidone arm. This is because
overall, the patients in the amisulpride arm were observed
to make a larger number of transitions; this might imply that
all effects of amisulpride (both beneficial and harmful) take
place relatively more quickly than that of risperidone.
Another interesting (although expected) result is that both
dropout rates are much higher for nonresponders than for
responders (γ13> γ23): Patients not getting well tend to leave
the study at higher rates regardless of the treatment they
receive, another indication that dropout is related to response.
Figure 2 depicts the fit of the model; the lines correspond
to the 3‐state model estimates for the probabilities of transi-
tion as a function of time, obtained from Equations 2 to 4;
dots correspond to the actual proportion of patients found at
each state at each time point in the study. Given that all
patients start at state 1 at time 0, these observed proportions
correspond to estimates for π11 ,π12, and π13. In section 5 of
the Appendix, we provide graphs for the time dependency
of all transition probabilities. In Table 3, we present various
measures estimated from the 3‐state model:
• OR13 for dropout (π1 , 3) at study's endpoint (8 weeks).
• OR12 for (observed) response at study's endpoint
(8 weeks), calculated by using π1 , 2 for each arm.
• OR23 for a responder to dropout within 8 weeks after
responding. This is calculated by using π2 , 3(Δt=8) for
each arm.
• OR21, for a responder to be found in the nonresponse
state 8 weeks after responding. This is calculated by using
π2 , 1(Δt=8) for each arm.
• Expected time spent (ETSX) on each state X for each
treatment for the duration of the study.
According to the median estimates presented in Table 3,
amisulpride is only slightly better than risperidone in response
among completers (OR12 = 0.94, 95% CrI 0.54 to 1.60), even
though γ12 is considerably higher for amisulpride; this is
because both γ21 and γ23 are higher for this drug, so that
responders tend to relapse and drop out more often. Regarding
dropout, the median estimate is OR13 = 0.81 (95% CrI 0.45 to
1.50), suggesting risperidone to be slightly better, that is,
associated with a smaller probability of study discontinuation.
Regarding responders dropping out, the model estimates an
TABLE 2 Median Estimates and 95% Credible Intervals (CrI) for the
Transition Rates and the Relative Treatment Effects Regarding the Log
Transition Rate Ratios for the 3‐State Model
Amisulpride Risperidone
Median 95% CrI Median 95% CrI
γ12 0.189 [0.143; 0.248] 0.136 [0.100; 0.180]
γ13 0.052 [0.032; 0.077] 0.047 [0.030; 0.070]
γ21 0.076 [0.042; 0.127] 0.056 [0.028; 0.196]
γ23 0.024 [0.009; 0.049] 0.009 [0.002; 0.027]
Transition rate ratios
Median 95% CrI
γRis12 =γ
Ami
12 0.72 [0.48; 1.07]
γRis13 =γ
Ami
13 0.92 [0.51; 1.64]
γRis21 =γ
Ami
21 0.73 [0.31; 1.62]
γRis23 =γ
Ami
23 0.39 [0.06; 1.83]
FIGURE 2 Model estimates from the 3‐state model (lines) and actual observations in the data (dots). The y‐axis shows the probability of a patient being found
in each state as a function of time (shown on the x‐axis). Dashed lines and white dots for amisulpride, thick lines and black dots for risperidone
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OR23 = 0.48 (CrI 0.17 to 1.41), with values smaller than 1
corresponding to amisulpride being associated with higher
probability of a responder dropping out. Finally, there is no
notable difference among the treatments regarding relapse,
OR21 = 0.96 (CrI 0.42 to 2.15). Note that all of these estimates
correspond to 8 weeks after responding. If deemed clinically
interesting, then the model can provide estimates at different
time points and the time dependency of the relative treatment
effects can also be plotted.
Using the ETS in each state for each treatment, we can
also calculate percentages of stay in each state. Patients on
amisulpride spend on average 50% of the time in nonre-
sponse, 35% in response and 15% of the study. Patients in
the risperidone arm spend on average 56% of the time in
the nonresponse state, 30% in the response and 14% to the
study‐discontinuation state.
We also use the various versions of the 4‐state model
depicted in Figure 1 to estimate the following:
• ORMCARresponse for the probability of either observed or unob-
served response (π1 , 2+ π1 , 5) at the study's endpoint
(8 weeks), under the MCAR scenario. We first fit the
3‐state model setting γ13= γ23, and we estimate the transi-
tion rates γ12 , γ21, and γ13= γ23. We then use these
estimates to calculate the probabilities of transition for
the 4‐state model after setting γ14= γ25=γ13, γ54= γ21,
and γ24= γ15=0.
• ORMARresponse for observed or unobserved response
(π1 , 2 + π1 , 5) at the study's endpoint (8 weeks), under
the MAR scenario of section 3.6. We first fit the 3‐state
model by assuming γ13≠ γ23 and then use the 4‐state
model, setting γ14= γ15=0.5 γ13, γ24= γ25=0.5 γ23, and
γ45= γ12, γ54= γ21.
• ORMNARresponse for either observed or unobserved response
(π1 , 2 + π1 , 5) at study's endpoint (8 weeks), under an
MNAR scenario. We first fit the 3‐state model, and we
then assume γ14=0.9γ13, γ15=0.1γ13, γ24=0.9γ23,
γ15=0.1γ23, γ45=0.1γ12, and γ54=2γ21. These choices
of the parameters correspond to a scenario where 90%
of patients that drop out of the study go to the unobserved
nonresponse state and where dropout patients tend to stay
to the nonresponse state.
The results from these scenarios are presented in Table 3.
We also include in this table the estimate for ORMMRMresponse
corresponding to the MMRM described by Equation 9, as
well as the LOCF and the CCA estimates.
The results show considerable differences among the var-
ious models regarding point estimates. When we adopted an
MNAR mechanism, assuming that dropout patients were
more probable to end up in nonresponse for both treatments,
the OR was closer to 1, as expected. Regarding precision, the
LOCF and CCA analyses showed the narrowest confidence
intervals. This was also anticipated, because these 2
approaches do not include any uncertainty regarding the
unobserved data. The MAR approach of the 4‐state model
gave a point estimate similar to the one obtained by using
the MMRM (which also assumes MAR). However, the 4‐
state model showed a considerable increase in precision
compared with MMRM.
To summarize, we conclude that the model suggests
amisulpride to be associated with a slightly higher response
(even though the difference is not statistically significant).
This effect is less pronounced under the illustrative MNAR
scenario. Moreover, amisulpride patients tend to drop out
more. Relapsing probability has been found to be comparable
across treatments.
5 | DISCUSSION
This paper addresses the problem of missing data in random-
ized control studies by introducing a method based on
TABLE 3 Model Estimates for Various Relative Treatment Effects at Study's Endpoint (8 weeks)
Model used Measure Median (95% CrI)
3‐state model OR13 (values <1 favor risperidone) 0.81 [0.45; 1.50]
OR12 (values <1 favor amisulpride) 0.93 [0.54; 1.60]
OR23 (values <1 favor risperidone) 0.48 [0.17; 1.41]
OR21 (values <1 favor risperidone) 0.96 [0.42; 2.15]
ETS1Expected time of stay is state 1 (weeks) Amisulpride 4.0 [3.5; 4.5]
Risperidone 4.5 [4.0; 5.0]
ETS2Expected time of stay is state 2 (weeks) Amisulpride 2.8 [2.2; 3.3]
Risperidone 2.4 [1.9; 3.0]
ETS3Expected time of stay is state 3 (weeks) Amisulpride 1.2 [0.8; 1.7]
Risperidone 1.1 [0.7; 1.5]
4‐state model ORMCARresponse (values <1 favor amisulpride) 0.76 [0.42; 1.38]
ORMARresponse (values <1 favor amisulpride) 0.82 [0.47; 1.41]
ORMNARresponse (values <1 favor amisulpride) 0.93 [0.53; 1.50]
MMRM ORMMRMresponse (values <1 favor amisulpride) 0.83 [0.35; 1.96]
CCA ORCCAresponse (values <1 favor amisulpride) 0.68 [0.35; 1.30]
LOCF ORLOCFresponse (values <1 favor amisulpride) 0.78 [0.47; 1.32]
All odds ratios are for risperidone (numerator) versus amisulpride (denominator).
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multistate Markov models. Our method allows a variety of
clinically interesting relative effect measures to be estimated.
It can be used to analyze individual participant data on a
binary outcome reported at multiple time points, taking into
account patients dropping out of the study prematurely as
well as information on patients relapsing.
The approach presented here is different than the methods
usually applied in the literature for analyzing datasets with
missing outcomes. It is focused on modeling the paths
patients follow and estimates the probability associated with
each path. All estimates follow from a small number of
parameters, the transition rates. Assumptions on the unob-
served outcomes of patients dropping out can be included
in the model on a second stage, after estimating the model's
parameters. This is achieved by introducing a set of hidden
states as we discussed in section 3.6. Using this 4‐state
model, one can readily model the missingness mechanism
and incorporate assumptions about unobserved responses of
patients that dropped out of the study.
We believe that the proposed method offers considerable
advantages compared with currently available methods for
handling missing outcomes. First, it can provide a wide range
of clinically interesting effect measures and give estimates on
their time dependency. The 4‐state model allows for a great
flexibility in modeling dropout. In addition, the correlations
between all effect measures are automatically incorporated
in the model and can be easily estimated by using the code
we used for the analysis, which we provide in the Appendix.
This is particularly valuable for the case of a meta‐analysis or
a network meta‐analysis of these measures. When these
correlations are not reported—currently the case in most
studies[27,28]—meta‐analysts need to resort to complex
modeling to correctly account for them.[29–33] Also, when
studies have different durations, our method can be used to
estimate treatment effects for each study at a predefined time
before pooling them together in a meta‐analysis.
Our approach is based on the Markov assumption, which
implies that the future path of a patient depends only on the
present state. This assumption may be more plausible in dis-
ease areas where past states of response or nonresponse are
expected to have small carry‐over effects on future disease
process. Moreover, it might be a suitable assumption to make
for the case of chronic conditions, where patients undergo
transitions between health states, for example, movements
among depressive, manic, and normal states in patients with
bipolar disorder. Clinical judgment should be used to assess
the plausibility of this assumption depending on the medical
context. Note that the Markov assumption can be relaxed if
deemed necessary by using several methods; for a discussion,
see Ref [34]. For example, instead of assuming that patients
relapse from the response state back to nonresponse, it might
be appropriate to include an additional relapse state in the
model. This would account for different future trajectories
depending on whether or not patients had responded in the
past. Also, we assumed that transition rates remain constant
over time, which might be unrealistic for certain clinical con-
ditions, especially for trials with long follow‐up. When this is
the case, the proposed methodology can be extended to allow
for piecewise constant rates within smaller time periods. In
our illustrative example, we could relax the assumption of
constant rates to be within time strata, for example, corre-
sponding to first week, 1 to 2 weeks, 2 to 4, 4 to 6, and 6
to 8 weeks. Including different transition rates within each
stratum will, of course, improve the fit of the model to the
data, at the expense of model complexity. In real‐life practical
applications, researchers might want to explore the trade‐off
between fit of the model and complexity, using model selec-
tion criteria such as deviance information criterion (DIC).
Another important limitation of the method we presented is
that it requires individual patient data (IPD) to be available.
Given that IPD are usually not reported in published studies,
if the proposed analysis is not implemented at study level,
then it will be hard to use it within a meta‐analysis.
We followed a Bayesian approach to model fitting, and
we used WinBUGS. This choice allows for increased flexibil-
ity in modeling, but this does not come without a cost: The
code we present in the Appendix is computationally intensive
and might be slow to converge, especially for very large stud-
ies and when multiple covariates are included in the model.
In principle, one could instead estimate the model parameters
by using maximum likelihood estimate,[13,23] for example,
using the msm package in R[20]; however, further applied
research is needed before the Bayesian implementation of
the models presented in this paper can be compared with their
frequentist counterparts.
The method presented in this paper could be extended to
allow for additional states, if this is supported by the data.
Let us assume, for example, that a study provides information
on the reason of dropping out for each patient: due to side
effects, due to lack of efficacy, or due to other reasons. For this
case, a 5‐state model, with 3 distinct out‐of‐the‐study states,
could be used. One should keep in mind, however, that adding
states will, in general, lead to models that cannot be analyti-
cally solved by using Kolmogorov forward equation. In this
case, a numerical solution can be performed instead,[19] using
WinBUGS Differential Interface, available from http://
winbugs‐development.mrc‐bsu.cam.ac.uk/wbdiff.html.
An additional measure that can be calculated by using the
methods presented in this paper is the mean quality‐adjusted
duration in each state.[35,36] This can be computed from the
ETS for each state after weighting them by a quality rate
associated with the burden or desirability of each state.
Another possible extension to the methodology presented
here is about combining results from multiple studies in a
meta‐analysis (or a network meta‐analysis when trials com-
paring different sets of competing treatments are available).
Price et al. propose a meta‐analytical framework for Markov
models based on parameterizing relative treatment effects
regarding log transition rates instead of probabilities.[24] It
would be interesting to explore methods for synthesizing
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information from studies for which IPD are available together
with information coming from studies providing only aggre-
gated data into a single, joint meta‐analysis. Finally, a simu-
lation study would be a very useful follow‐up to the work
presented in this paper, as it would allow the evaluation of
the performance of the presented methods in comparison with
alternative, established methods for analyzing incomplete
dichotomous data.
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